

Full Paper

Investigation of the role of *SDHB* inactivation in sporadic phaeochromocytoma and neuroblastoma

D Astuti¹, M Morris^{1,2}, C Krona³, F Abel³, D Gentle^{1,2}, T Martinsson³, P Kogner⁴, HPH Neumann⁵, R Voutilainen^{6,7}, C Eng⁸, P Rustin⁹, F Latif^{1,2} and ER Maher^{*,1,2}

¹Section of Medical and Molecular Genetics, Department of Paediatrics and Child Health, University of Birmingham, The Medical School, Edgbaston, Birmingham B15 2TT, UK; ²Cancer Research UK Renal Molecular Oncology Research Group, University of Birmingham, The Medical School, Edgbaston, Birmingham B15 2TT, UK; ³Department of Clinical Genetics, Gothenburg University, Sahlgrenska University Hospital/Ostra, S-416 85 Gothenburg, Sweden; ⁴Childhood Cancer Research Unit, Department of Woman and Child Health, Karolinska Institute, Karolinska Hospital, S-171 76 Stockholm, Sweden; ⁵Medizinische Universitätsklinik, Hugstetter Str. 55, D-79106 Freiburg, Germany; ⁶Department of Paediatrics, Kuopio University Hospital, FIN-70211 Kuopio, Finland; ⁷Department of Pathology, Haartman-Institute, FIN-00014 University of Helsinki, Helsinki, Finland; ⁸Clinical Cancer Genetics and Human Cancer Genetics Programs, Comprehensive Cancer Center, the Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA; ⁹INSERM U393 Handicaps Génétique de l'Enfant, Hôpital Necker-Enfants Malades, 149, rue de Sèvres, 75015 Paris, France

Germline mutations in the succinate dehydrogenase (SDH) (mitochondrial respiratory chain complex II) subunit B gene, *SDHB*, cause susceptibility to head and neck paraganglioma and phaeochromocytoma. Previously, we did not identify somatic *SDHB* mutations in sporadic phaeochromocytoma, but *SDHB* maps to 1p36, a region of frequent loss of heterozygosity (LOH) in neuroblastoma as well. Hence, to evaluate *SDHB* as a candidate neuroblastoma tumour suppressor gene (TSG) we performed mutation analysis in 46 primary neuroblastomas by direct sequencing, but did not identify germline or somatic *SDHB* mutations. As TSGs such as *RASSF1A* are frequently inactivated by promoter region hypermethylation, we designed a methylation-sensitive PCR-based assay to detect *SDHB* promoter region methylation. In 21% of primary neuroblastomas and 32% of phaeochromocytomas (32% methylated (and unmethylated) alleles were detected. Although promoter region methylation was also detected in two neuroblastoma cell lines, this was not associated with silencing of *SDHB* expression, and treatment with a demethylating agent (5-azacytidine) did not increase SDH activity. These findings suggest that although germline *SDHB* mutations are an important cause of phaeochromocytoma susceptibility, somatic inactivation of *SDHB* does not have a major role in sporadic neural crest tumours and *SDHB* is not the target of 1p36 allele loss in neuroblastoma and phaeochromocytoma.

British Journal of Cancer advance online publication, 26 October 2004; doi:10.1038/sj.bjc.6602202 www.bjcancer.com

© 2004 Cancer Research UK

Keywords: *SDHB*; methylation; neuroblastoma; phaeochromocytoma

Neuroblastoma and phaeochromocytoma are the most common neural crest-derived tumours in children and adults, respectively. Neuroblastoma is clinically variable with some tumours demonstrating spontaneous regression after little or no therapy, while in other cases distant metastases are present at diagnosis. Familial neuroblastoma is rare and major susceptibility genes have not yet been isolated. Phaeochromocytomas usually present with hypertension and 90% are benign. Germline mutations in the *RET*, *VHL*, *SDHB* and *SDHD* genes are important causes of phaeochromocytoma susceptibility and phaeochromocytoma may also rarely (<1%) complicate neurofibromatosis type 1 (reviewed by Maher and Eng 2002, Eng *et al*, 2003). Human cancer genetics provides many examples of how the identification of a rare inherited cancer susceptibility gene has provided insights into the pathogenesis of

sporadic cases. However, exceptions exist: although von Hippel–Lindau disease is a major cause of familial clear cell renal carcinoma (cRCC) and somatic inactivation of the *VHL* tumour suppressor gene (TSG) occurs in most sporadic cRCC (Gnarra *et al*, 1994; Foster *et al*, 1994; Herman *et al*, 1994; Clifford *et al*, 1998), somatic *VHL* inactivation by mutation or methylation of the promoter region is infrequent (<5%) in sporadic phaeochromocytomas. In addition, although both phaeochromocytoma and medullary thyroid cancer are major features of MEN 2A and MEN 2B and somatic *RET* mutations are common in sporadic medullary thyroid cancer (Eng *et al*, 1994, 1995), somatic *RET* mutations are found in only 10% of sporadic phaeochromocytomas (Eng *et al*, 1995; Hofstra *et al*, 1996). Thus, *VHL* and *RET* appear to have only a minor role in the pathogenesis of sporadic phaeochromocytoma.

The *SDHB* and *SDHD* genes encode two (of four) subunits of the mitochondrial respiratory chain complex II (succinate dehydrogenase: SDH). Germline mutations in *SDHB* and *SDHD*, in addition to causing phaeochromocytoma, may also predispose to the development of head and neck paragangliomas (most commonly

*Correspondence: Professor ER Maher; E-mail: E.R.Maher@bham.ac.uk
Received 10 May 2004; revised 31 August 2004; accepted 2 September 2004

carotid body tumours) (Baysal *et al*, 2000; Gimm *et al* 2000, Astuti *et al*, 2001a, b, 2003; Gimenez-Roqueplo *et al*, 2002; Neumann *et al*, 2002, Benn *et al*, 2003; Leube *et al*, 2004). Familial pheochromocytoma or head and neck paraganglioma (HNPGL) kindreds with germline *SDHD* mutations demonstrate parent-of-origin effects on penetrance (Baysal *et al*, 2000; Astuti *et al*, 2001a). In contrast, *SDHB* mutations show no evidence of genomic imprinting effect. *SDHB* maps to 1p36, a region of frequent allele loss in many tumour types including neuroblastoma and pheochromocytoma (Martinsson *et al*, 1997; Maris and Matthay, 1999; Benn *et al*, 2000; Ejeskar *et al*, 2001). Previously, we did not detect somatic *SDHB* mutations in 24 sporadic pheochromocytomas (Astuti *et al*, 2001b) and this has been confirmed by others (Benn *et al*, 2003). However, studies of a number of TSGs have established a paradigm in which specific TSGs can be inactivated frequently by *de novo* promoter methylation but rarely by somatic mutations (Dammann *et al*, 2000; Agathangelou *et al*, 2001; Burbee *et al*, 2001; Morrissey *et al*, 2001). In keeping with this, we have reported frequent *RASSF1A* hypermethylation in neuroblastoma and pheochromocytoma (Astuti *et al*, 2001c). These findings prompted us to investigate whether *SDHB* promoter methylation occurred in neuroblastoma and pheochromocytoma.

MATERIALS AND METHODS

Clinical material

DNA were extracted from frozen primary tumour tissue from (a) 35 sporadic pheochromocytomas without evidence of germline or somatic *SDHB* mutations (four tumours were from patients with von Hippel – Lindau disease and three from patients with MEN2A) and one pheochromocytoma with a germline *SDHB* mutation was analysed (Astuti *et al*, 2001b); (b) 46 neuroblastomas and (c) from corresponding normal tissue samples (fibroblast or blood) were analysed. Approval from the appropriate Institutional Review Boards and informed consent from all patients were obtained. Most of this tumour material has been described earlier (Martinsson *et al*, 1997; Ejeskär *et al*, 1998; Astuti *et al*, 2001c).

Bisulphite modification and methylation-specific PCR (MSP)

Bisulphite DNA modification was performed as described previously (Herman *et al*, 1996). Briefly, 0.5–1.0 µg of genomic DNA was denatured in 0.3 M NaOH for 15 min at 37°C and then unmethylated cytosine residues were sulphonated by incubation in 3.12 M sodium bisulphite (pH 5.0) (Sigma) 5 mM hydroquinone (Sigma) in a thermocycler (Hybaid) for 30 s at 99°C/15 min at 50°C for 20 cycles. The sulphonated DNA was recovered using the Wizard DNA clean-up system (Promega) in accordance with the manufacturer's instructions. The conversion reaction was completed by desulphonating in 0.3 M NaOH for 10 min at room temperature. The DNA was ethanol precipitated and resuspended

in water. Methylation-specific PCR was performed using specific primers designed to amplify methylated and unmethylated putative *SDHB* promoter sequences (Au *et al*, 1995; GeneBank accession No. U17296): unmethylated – specific, 5'-TGTGTTGTTA TTGTGTTATTGTGTAT-3' (forward) and 5'-CCACCAAAAATTA TAACCAACAACCA-3' (reverse) and methylated – specific, 5'-TGCG TCGTTATTGCGTTATTGCGTAC-3' (forward) and 5'-CCGCCAAA AATTATAACCGACAACCG-3' (reverse) (Figure 1). Taq DNA polymerase (Gibco) was added after a 'hot start' at 95°C for 5 min. Amplification was carried out for 35 cycles at an annealing temperature of 53°C for the unmethylated specific primers and 61°C for the methylated specific primers on Omn-E (Hybaid) DNA thermal cycler. The expected sizes of the PCR products for both unmethylated and methylation-specific amplifications were 269 bp.

Cloning and sequencing of PCR products

The PCR products containing bisulphite-resistant cytosines were purified using PCR product purification kit (Qiagen) and ligated into the pGEM-T easy vector system (Promega), according to the manufacturer's instructions. Several clones were then isolated and sequenced using ABI 377 DNA analyser (Applied Biosystem).

Mutation analysis *SDHB* mutation analysis was performed by direct sequencing of coding sequence amplicons as previously described (Astuti *et al*, 2001b). The GenBank accession number for *SDHB* exons 1–8 are: U17296, U17880, U17881, U17882, U17883, U17884, U17885 and U17886. Sequence analysis was performed on an ABI PRISM 3100 DNA Sequencer (Applied Biosystems). The sequencing products were compared to the *SDHB* reference sequence NM_003000.

Cell culture and Western blot analysis

Two neuroblastoma cell lines (SK-N-AS and SK-N-SH) purchased from ATCC were grown in Dulbecco's modified eagle medium, supplemented with 10% foetal calf serum. Demethylation was performed by the addition of 2 µM 5-aza-2-deoxycytidine to the growth medium. This latter was replenished with fresh medium after 3 days. On the fifth day of treatment, total protein was extracted in NETS lysis buffer (150 mM NaCl, 50 mM Tris (pH 8) 5 mM EDTA, 1% NP40) containing 3 mM PMSF, 20 µg ml⁻¹ aprotinin and 10 µg ml⁻¹ leupeptin. Following homogenisation and incubation on ice for 10 min, lysates were centrifuged for 15 min at 14 000 rpm/4°C and stored at –20°C.

Protein samples (20 µg each) were separated on sodium dodecyl sulphate-10.5% polyacrylamide gel and electroblotted to transblot polyvinylidene difluoride membrane (Hybond-P; Amersham Bioscience, Chalfont St Giles, UK). Anti-*SDHB* (Molecular Probes, clone: 21A11-AE7) at 2.5 µg ml⁻¹ was applied followed by rabbit anti-mouse immunoglobulin-peroxidase conjugate. Visualisation was carried out by the enhanced chemiluminescence detection system (ECL-plus; Amersham Bioscience). The filter



Figure 1 *SDHB* promoter sequence. In boxes shaded in light grey are the MSP primer sequences. CpG islands are in bold and numbered from 1 to 23. The numbers in brackets are nucleotide position in relation to the ATG start codon (highlighted in light grey).

was stained with India ink for standardisation, and quantification was performed using a Bio-Rad imaging densitometer with Quantity One software.

Enzyme assays Succinate cytochrome *c* reductase (complex II and III) and quinol cytochrome *c* reductase (complex III) activities were spectrophotometrically measured in neuroblastoma cell line homogenates as previously described (Rustin *et al*, 1994).

Loss of heterozygosity (LOH) analysis

Assessment of neuroblastoma samples for 1p loss of heterozygosity (LOH) has been reported previously (Martinsson *et al*, 1995, 1997; Ejeskär *et al*, 2001). The 1p allele status of the pheochromocytoma samples was investigated using a panel of 14 polymorphic microsatellite markers, including 1pter-D1S243, D1S1646, D1S1635, D1S434, D1S1597, D1S228, D1S552, D1S1676, D1S1622, D1S2134, D1S1661, D1S1596, D1S551 and D1S435-1cen. Primer sequences are available from the Genome Database (<http://gdbwww.gdb.org>). The PCR products were electrophoresed on an 8% urea – polyacrylamide gel and were visualised by silver staining. Allelic loss was considered to have occurred in tumour samples when there was a 50% or greater reduction in signal intensity of an allele in tumour DNA compared to normal DNA.

Statistical analysis Comparisons were made by Fisher's exact test (two tailed). *P*-values of 0.05 were taken as statistically significant.

RESULTS

SDHB methylation and mutation status in neuroblastoma

Direct sequencing of the *SDHB* coding exons and flanking sequences in 46 neuroblastoma tumours was performed. No pathogenic mutations were detected, although a number of known sequence variants and deviations from reference sequence were detected. One silent heterozygous SNP (18A > C) was identified in a stage 4 neuroblastoma with a fatal outcome of the disease. Some

variations from the reference sequence (c.-16delG, IVS3-(18-19) insA, IVS3-(24-25) insA, IVS7 + 4delA, and IVS8 + (19-20) insT) were present in homozygous form in all samples including the control, and they are thus likely to be errors in the reference sequence. A trinucleotide repeat, TTC_n, with the most 3' nucleotide located 14 bases upstream of exon 5 was found to be polymorphic. The number of repeats varied between 6 and 10 with 8 repetitions being the most common allele. Of 94 neuroblastoma tumour samples tested, 91 were homozygous (or hemizygous) TTC₈ compared to 98 out of 99 control samples.

SDHB promoter methylation status was investigated in 46 primary neuroblastoma tumours. In all, 22% (10 out of 46) of the neuroblastomas demonstrated *SDHB* CpG island promoter methylation by MSP analysis compared to 0 of 20 normal control blood samples. Sequencing of the MSP product (10 individual clones from two methylated tumours) demonstrated that 22 of the 23 CpG dinucleotides in the fragment were methylated in each tumour (Figure 2). In each tumour with *SDHB* methylation, unmethylated alleles were also detected so there was no evidence of complete methylation. There was no significant difference between the frequency of *SDHB* promoter methylation in neuroblastoma tumours with and without 1p36 allele loss and no correlation with 3p allele loss, 17q gain or N-myc amplification status. Furthermore, there was no association between partial *SDHB* promoter methylation and tumour stage (21% of stage 1, 2 and 4S tumours, and in 27% of stage 3 and 4 tumours).

1pLOH analysis and *SDHB* promoter methylation in sporadic pheochromocytomas

Previously we did not find evidence of somatic *SDHB* mutations in sporadic pheochromocytomas (Astuti *et al*, 2001b). However, to investigate further the potential role of *SDHB* in the pathogenesis of pheochromocytoma, we determined the frequency, extent and patterns of 1p allele loss in 36 sporadic pheochromocytomas using 14 polymorphic microsatellite markers mapping to 1p22–1p36. In all, 75% (27/36) of tumours demonstrated LOH at one or more 1p locus (Figure 3). A total of 10 tumours demonstrated LOH




Figure 2 (A) Partial chromatogram of cloned MSP product from a methylated neuroblastoma tumour (St158T). Methylated cytosine appear as a G signal in the complementary strand. The number indicates the position of CpG sites. (B) Similar chromatogram obtained from an unmethylated neuroblastoma tumour (St111T).

Location (Mb from pter)	Marker	Tumors																																											
		T1	T2	T3	T4	T5	T6	T7	T8	T9	T10	T11	T12	T13	T14	T15	T16	T17	T18	T19	T20	T21	T22	T23	T24	T25	T26	T27	T28	T29	T30	T31	T32	T33	T34	T35	T36								
1.9	D1S243	●	●	●	●	●	●	●	●	●	○	○	●	●	●	●	●	●	●	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○					
6.7	D1S1646	●	●	●	●	●	○	●	●	●	●	●	○	○	○	○	●	●	●	●	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○				
10.6	D1S1635	●	●	●	○	○	○	●	●	●	●	●	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○				
11.9	D1S434	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○				
13.0	D1S1597	●	●	●	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○				
SDHB	13.2 D1S228	●	●	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○				
	18.6 D1S552	●	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○			
24.6	D1S1676	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○		
29.7	D1S1622	●	●	●	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○		
47.5	D1S2134	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	
50.7	D1S1661	●	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	
59.0	D1S1596	●	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○
82.2	D1S551	●	●	●	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○
90.9	D1S435	●	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○

Figure 3 Summary of chromosome 1p loss of heterozygosity analysis in pheochromocytomas. Filled circles indicate LOH; shaded circles indicate retention of heterozygosity and open circles indicate noninformative cases. Microsatellite markers are ordered from telomere to centromere (Genome Browser-Human assembly, July 2003; <http://genome.ucsc.edu>).




Figure 4 MSP analysis of *SDHB* methylation in sporadic neuroblastoma (St111T, St158T and St119T) tumours and in sporadic pheochromocytoma (T29, T33, T21 and T20) tumours. Bisulphite-modified DNA was amplified with primer pair specific for unmethylated (U) and methylated (M) alleles as described in the text. *In vitro* methylated DNA was used as a positive control (+) for amplification with methylated DNA-specific primers.

at all informative markers and nine demonstrated retention at all informative markers. *SDHB* maps between D1S228 and D1S552 (~1.7 MB from D1S552) and LOH was observed in 54 and 64%, respectively, of informative tumours at these flanking markers. A pheochromocytoma sample with a germline *SDHB* mutation demonstrated 1p allele loss (and no methylation, T12 – see later) consistent with a ‘two hits’ model of tumourigenesis.

SDHB promoter methylation was detected in nine out of 28 (32%) of pheochromocytomas analysed by MSP (all matching blood DNA samples were unmethylated) (Figure 4). In addition to methylation-specific PCR products, unmethylated-specific products were also amplified from each of the nine ‘methylated tumours’ consistent with partial methylation in tumours and/or the presence of contaminating normal tissue in the tumour samples. Sequencing of the MSP product (10 individual clones from each of two methylated pheochromocytomas) demonstrated methylation at 21 of the 23 CpGs analysed (data not shown). There was no difference between the frequency of LOH close to *SDHB* in pheochromocytoma with and without *SDHB* promoter methylation (75 vs 57% respectively, $P=0.42$).

Functional significance of *SDHB* promoter region methylation

To investigate the possible functional significance of this partial promoter methylation, we screened eight neuroblastoma cell lines and identified two (SK-N-SH and SK-N-AS) with partial *SDHB* methylation by MSP. We then treated these two cell lines with the




Figure 5 Expression analysis of *SDHB* gene in neuroblastoma cell line SK-N-AS and SK-N-SH, before (–) and after (+) 5-aza-2-deoxycytidine treatment. Western blotting was performed essentially as described in the Material and Methods. Indian ink staining was included as a loading control.

demethylating agent, 5-azacytidine, for 5 days and evaluated the effect on *SDHB* protein expression. Before treatment, *SDHB* was readily detectable and following treatment with 5-azacytidine, there were small increases in *SDHB* protein expression (*SDHB* protein (up to three- and two-fold in SK-N-SH and SK-N-AS cells respectively) (Figure 5). However, the relatively small changes in *SDHB* expression were not associated with evidence of enhanced SDH enzyme activity. Thus, the ratio of quinol cytochrome *c* reductase (complex III) (QCCR) to succinate cytochrome *c*

reductase (complex II and III) (SCCR) enzyme activities was not abnormally increased prior to treatment with 5-aza-2-deoxycytidine, and there was no reduction in QCCR/SCCR ratio after demethylation (SK-N-SH cell line: Pretreatment QCCR/SCCR ratio = 2.13, post-treatment 3.7; SK-N-AS cell line, pretreatment QCCR/SCCR ratio = 2.85, post-treatment 3.44; controls (lymphoblastoid cell lines: QCCR/SCCR ratio = 3.1 ± 0.3).

DISCUSSION

Neuroblastomas and pheochromocytomas are the most common neural crest-derived tumours in children and adults, respectively, and it is of interest to compare the molecular pathology of the two tumours. The molecular pathology of sporadic neuroblastomas has been investigated extensively. Frequent alterations include N-myc amplification (20–25%) and gain of genetic material at 17q23 – qter (–50% of tumours). Neuroblastoma suppressor genes have been mapped by LOH studies to 1p36 (30–35% of primary tumours show LOH), 11q23 (44%) and 14q231 – qter (22%) (reviewed in Maris and Matthay, 1999). In addition to these well-defined genetic alterations, we and others have demonstrated that epigenetic TSG inactivation may be a feature of neuroblastoma. Thus, *CASP8* promoter methylation has been reported in ~50% of neuroblastomas by us and other (Teitz *et al*, 2000; Astuti *et al*, 2001c; Harada *et al*, 2002a) and *RASSF1A* promoter methylation also occurs frequently (52–55%) (Astuti *et al*, 2001c; Harada *et al*, 2002b). However, Harada *et al* (2002b) detected no or little promoter methylation of *p16^{INK4A}* (0%), *MGMT* (0%), *RARB* (0%), *DAPK* (0%), *APC* (0%), *CDH13* (0%), *CDH1* (6%) and *GSTP1* (3%) in primary neuroblastoma tumours. These genes have all demonstrated promoter methylation in other cancer types and so most TSGs analysed to date do not show promoter methylation in neuroblastoma.

Although there is compelling evidence for a major neuroblastoma suppressor gene on 1p, to date, a major 1p36.2 – p36.3 neuroblastoma suppressor gene has not been identified (Ejeskär *et al*, 1999; Jogi *et al*, 2000; Abel *et al*, 2002). We did not detect somatic *SDHB* gene mutations in neuroblastoma and we could not demonstrate evidence for epigenetic inactivation. In addition, we note that the critical neuroblastoma suppressor gene interval defined by Ejeskär *et al* (2001) (D1S508 to D1S244) and the 500 kb 1p36.2 – p36.3 homozygous deletion in a neuroblastoma cell line reported by Ohira *et al* (2000), both map >4 Mb telomeric to *SDHB*. *CASP8* and *RASSF1A* methylation in neuroblastoma is associated with transcriptional downregulation, but in contrast *SDHB* promoter methylation did not impair SDH enzyme activity. We note that despite tumour-specific *WT1* promoter methylation in primary breast cancer, WT1 protein is still expressed in these tumours (Loeb *et al*, 2001). While MSP provides a sensitive technique for detecting promoter methylation in tumour samples, the ability to detect low levels of methylation, in only a subset of tumour cells, can exaggerate the frequency of promoter methylation.

Even though germline *SDHB* mutations are an important cause of pheochromocytoma susceptibility (Astuti *et al*, 2001b; Neumann *et al*, 2002), we did not identify somatic *SDHB* mutations in pheochromocytoma so far. Similarly, germline mutations in the *VHL* TSG are an important cause of pheochromocytoma

susceptibility, but somatic *VHL* mutations are rare in pheochromocytoma (Eng *et al*, 1995; Woodward *et al*, 1997). The finding of 1p LOH in a pheochromocytoma with a germline *SDHB* mutation is consistent with a two hit hypothesis of tumorigenesis and the frequent occurrence of 1p LOH in sporadic pheochromocytomas without *SDHB* mutations suggested that in some cases *SDHB* inactivation could occur by a combination of LOH and *SDHB* promoter methylation. However Benn *et al* (2000) have suggested that there were at least two distinct intervals (three possible regions) of 1p LOH in pheochromocytoma. *SDHB* maps outside the most telomeric distinct interval (PC1, D1S243 to D1S244) but is contained within the second interval (D1S228 to >40 cM centromeric). In our LOH studies, 10 tumours with partial 1p LOH had no LOH at D1S228 but LOH at more centromeric markers. *SDHB* maps ~4 Mb centromeric to D1S228 (<http://genome.ucsc.edu/cgi-bin/hgGateway>) so LOH studies did not exclude *SDHB* being implicated in pheochromocytoma tumorigenesis. As for chromosome 3p, multiple TSGs may map to 1p. We note that in several tumours there were complicated patterns of LOH with areas of LOH flanking a marker with retention of heterozygosity. Such patterns may reflect the involvement of multiple TSGs in a single tumour. Although we detected evidence for partial *SDHB* promoter methylation using the sensitive MSP technique in a subset of pheochromocytomas, this degree of methylation did not impair SDH activity (for comparison, Gimenez-Roqueplo *et al* (2002) found a mean QCCR/SCCR ratio of >200 in pheochromocytomas with *SDHB* mutations and 2.7 in pheochromocytomas without *SDHB* mutations).

The mechanism whereby germline *SDHB* mutations promote tumorigenesis is uncertain. *SDHB* inactivation may lead to upregulation of a wide range of hypoxia-inducible genes (Gimenez-Roqueplo *et al*, 2002). Activation of hypoxia-responsive pathways may have an important role in cancer development and may be caused by local tissue hypoxia or result from genetic mechanisms (An *et al*, 1998; Maxwell *et al*, 1999; Zundel *et al*, 2000). However, germline *VHL* mutations that cause pheochromocytomas and not other features of VHL disease retain the ability to regulate hypoxia-inducible factor HIF-1 and HIF-2 (Clifford *et al*, 2001; Hoffman *et al*, 2001). Mitochondrial dysfunction may reduce apoptosis and promote tumorigenesis (Green and Reed, 1998), and is another mechanism by which *SDHB* inactivation could promote tumorigenesis. Further work is required to define the precise mechanism of *SDHB* tumour suppression and how these explain the restricted phenotype of *SDHB*-associated tumours and the lack of evidence for a role of somatic *SDHB* inactivation in the pathogenesis of sporadic pheochromocytomas.

ACKNOWLEDGEMENTS

This work is supported by the British Heart Foundation (DA, FL, EM), Cancer Research UK (MM, FL, EM), Swedish Cancer Society, Swedish Children's Cancer Foundation (TM, PK), Deutsche Forschungsgemeinschaft Grant NE 571/5-2 and the Deutsche Krebshilfe Grant 70-3313-Ne 1 (HPH) and P30CA16058 from the National Cancer Institute, Bethesda, MD, USA (to The Ohio State University Comprehensive Cancer Center). CE is a recipient of the Doris Duke Distinguished Clinical Scientist Award.

REFERENCES

- Abel F, Sjöberg RM, Ejeskär K, Krona C, Martinsson T (2002) Analyses of apoptotic regulators *CASP9* and *DFFA* at 1P36.2, reveal rare allele variants in human neuroblastoma tumours. *Br J Cancer* **86**: 596–604
- Agathangelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER, Latif F (2001) Methylation associated inactivation of *RASSF1A* from region 3p21.3 in lung, breast and ovarian tumours. *Oncogene* **20**: 1509–1518
- An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM (1998) Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. *Nature* **392**: 405–408

- Astuti D, Douglas F, Lennard TW, Aligianis IA, Woodward ER, Evans DG, Eng C, Latif F, Maher ER (2001a) Germline SDHD mutation in familial pheochromocytoma. *Lancet* **357**: 1181–1182
- Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, Skoldberg F, Husebye ES, Eng C, Maher ER (2001b) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. *Am J Hum Genet* **69**: 49–54
- Astuti D, Agathangelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HPH, Voutilainen R, Dahia P, Eng C, Maher ER, Latif F (2001c) RASSF1A promoter region CpG island hypermethylation in pheochromocytomas and neuroblastoma tumours. *Oncogene* **20**: 7573–7577
- Astuti D, Hart-Holden N, Latif F, Laloo F, Black GC, Lim C, Moran A, Grossman AB, Hodgson SV, Freemont A, Ramsden R, Eng C, Evan DG, Maher ER (2003) Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and pheochromocytoma susceptibility. *Clin Endocrinol* **59**: 728–733
- Au HC, Ream-Robinson D, Bellew LA, Broomfield PLE, Saghbini M, Scheffler IE (1995) Structural organization of the gene encoding the human iron-sulfur subunit of succinate dehydrogenase. *Gene* **159**: 249–253
- Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN, Richard III CW, Cornelisse CJ, Devilee P, Devlin B (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. *Science* **287**: 848–851
- Benn DE, Dwight T, Richardson AL, Delbridge L, Bambach CP, Stowasser M, Gordon RD, Marsh DJ, Robinson BG (2000) Sporadic and familial pheochromocytomas are associated with loss of at least two discrete intervals on chromosome 1p. *Cancer Res* **60**: 7048–7051
- Benn DE, Crosson MS, Tucker K, Bambach CP, Richardson AL, Delbridge L, Pullan PT, Hammond J, Marsh DJ, Robinson BG (2003) Novel succinate dehydrogenase subunit B (SDHB) mutations in familial pheochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic pheochromocytomas. *Oncogene* **22**: 1358–1364
- Burbee DG, Forgacs E, Zöschbauer-Müller S, Shivakumar L, Gao B, Randle D, Virmani A, Bader S, Sekido Y, Latif F, Fong K, Gazdar AF, Lerman MI, White M, Minna JD (2001) Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. *J Natl Cancer Inst* **93**: 691–699
- Clifford SC, Prowse AH, Affara NA, Buys CHCM, Maher ER (1998) Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. *Gene Chromosome Cancer* **22**: 200–209
- Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER (2001) Contrasting effects on HIF-1 α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel–Lindau disease. *Hum Mol Genet* **10**: 1029–1038
- Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. *Nat Genet* **25**: 315–319
- Ejeskär K, Sjöberg RM, Abel F, Kogner P, Ambros PF, Martinsson T (2001) Fine mapping of a tumour suppressor candidate gene region in 1p36.2–3, commonly deleted in neuroblastomas and germ cell tumours. *Med Pediatr Oncol* **36**: 61–66
- Ejeskär K, Sjöberg RM, Kogner P, Martinsson T (1999) Variable expression and absence of mutations in p73 in primary neuroblastoma tumors argues against a role in neuroblastoma development. *Int J Mol Med* **3**: 585–589
- Ejeskär K, Aburatani H, Abrahamsson J, Kogner P, Martinsson T (1998) Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene. *Br J Cancer* **77**: 1787–1791
- Eng C, Crossey PA, Mulligan LM, Healey CS, Houghton C, Prowse A, Chew SL, Dahia PLM, O’Riordan JLH, Toledo SPA, Smith DP, Maher ER, Ponder BAJ (1995) Mutations in the RET proto-oncogene and the von Hippel–Lindau disease tumour suppressor gene in sporadic and syndromic pheochromocytomas. *J Med Genet* **32**: 934–937
- Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GF, Jackson CE, Tunnacliffe A (1994) Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. *Hum Mol Genet* **3**: 237–241
- Eng C, Kiuru M, Fernandez MJ, Aaltonen LA (2003) A role for mitochondrial enzymes in inherited neoplasia and beyond. *Nat Rev Cancer* **3**: 193–202
- Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MM, Crossey PA, Richards FM, Cairns P, Affara NA, Ferguson-Smith MA (1994) Somatic mutations of the von Hippel–Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. *Hum Mol Genet* **12**: 2169–2173
- Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Kerlan V, Plouin PF, Rotig A, Jeunemaitre X (2002) Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. *J Clin Endocrinol Metab* **87**: 4771–4774
- Gimm O, Armanios M, Dziema H, Neumann HP, Eng C (2000) Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. *Cancer Res* **60**: 6822–6825
- Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. *Nat Genet* **7**: 85–90
- Green DR, Reed JC (1998) Mitochondria and apoptosis. *Science* **281**: 1309–1312
- Harada K, Toyooka S, Shivapurkar N, Maitra A, Reddy JL, Matta H, Miyajima K, Timmons CF, Tomlinson GE, Mastrangelo D, Hay RJ, Chaudhary PM, Gazdar AF (2002a) Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. *Cancer Res* **62**: 5897–5901
- Harada K, Toyooka S, Maitra A, Maruyama R, Toyooka KO, Timmons CF, Tomlinson GE, Mastrangelo D, Hay RJ, Minna JD, Gazdar AF (2002b) Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. *Oncogene* **21**: 4345–4349
- Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM (1994) Silencing of the VHL tumour-suppressor gene by DNA methylation in renal carcinoma. *Proc Natl Acad Sci USA* **91**: 9700–9704
- Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. *Proc Natl Acad Sci USA* **93**: 9821–9826
- Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin Jr WG (2001) von Hippel–Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. *Hum Mol Genet* **10**: 1019–1027
- Hofstra RM, Stelwagen T, Stulp RP, de Jong D, Hulsbeek M, Kamsteeg EJ, van den Berg A, Landsvater RM, Vermeij A, Molenaar WM, Lips CJ, Buys CH (1996) Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases. *J Clin Endocrinol Metab* **81**: 2881–2884
- Jogi A, Abel F, Sjöberg RM, Toftgard R, Zaphiropoulos PG, Pahlman S, Martinsson T (2000) Patched 2, located in 1p32–34, is not mutated in high stage neuroblastoma tumors. *Int J Oncol* **16**: 943–949
- Leube B, Huber R, Goecke TO, Sandmann W, Royer-Pakora B (2004) SDHD mutation analysis in seven German patients with sporadic carotid body paraganglioma: one novel mutation, no Dutch founder mutation and further evidence that G12S is a polymorphism. *Clin Genet* **65**: 61–63
- Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, Buluwela L, Weitzman SA, Korz D, Sukumar S (2001) Wilms’ tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. *Cancer Res* **61**: 921–925
- Maher ER, Eng C (2002) The pressure rises: update on the genetics of pheochromocytoma. *Hum Mol Genet* **11**: 2347–2354
- Maris JM, Matthay KK (1999) Molecular biology of neuroblastoma. *J Clin Oncol* **17**: 2264–2279
- Martinsson T, Sjöberg RM, Hedberg F, Kogner P (1995) Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. *Cancer Res* **55**: 5681–5686
- Martinsson T, Sjöberg RM, Hallstenon K, Nordling M, Hedberg F, Kogner P (1997) Delimitation of a critical tumour suppressor region at distal 1p in neuroblastoma tumours. *Eur J Cancer* **33**: 1997–2001
- Maxwell PH, Wiesener MS, Chang GWW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature* **399**: 271–275
- Morrissey C, Martinez A, Zatyka M, Agathangelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F, Maher ER (2001) Epigenetic inactivation of the RASSF1A 3p21.3 tumor

- suppressor gene in both clear cell and papillary renal cell carcinoma. *Cancer Res* **61**: 7277–7281
- Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Althoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C, Eng C (2002) Germ-line mutations in nonsyndromic pheochromocytoma. *N Engl J Med* **346**: 1459–1466
- Ohira M, Kageyama H, Mihara M, Furuta S, Machida T, Shishikura T, Takayasu H, Islam A, Nakamura Y, Takahashi M, Tomioka N, Sakiyama S, Kaneko Y, Toyoda A, Hattori M, Sakaki Y, Ohki M, Horii A, Soeda E, Inazawa J, Seki N, Kuma H, Nozawa I, Nakagawara A (2000) Identification and characterization of a 500-kb homozygously deleted region at 1p36.2–p36.3 in a neuroblastoma cell line. *Oncogene* **19**: 4302–4307
- Rustin P, Chretien D, Gerard B, Bourgeron T, Rötig A, Saudubray JM, Munnich A (1994) Biochemical and molecular investigations in respiratory chain deficiencies. *Clin Chim Acta* **228**: 35–51
- Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. *Nat Med* **6**: 529–535
- Woodward ER, Eng C, McMahon R, Voutilainen R, Affara NA, Ponder BAJ, Maher ER (1997) Genetic predisposition to pheochromocytoma: analysis of candidate genes GDNF, RET and VHL. *Hum Mol Genet* **6**: 1051–1056
- Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D, Giaccia AJ (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. *Genes Dev* **14**: 391–396